BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25149524)

  • 1. Mutational Status of CDKN2A and TP53 Genes in Laryngeal Squamous Cell Carcinoma.
    Todorova TA; Jordanov SH; Stancheva GS; Chalakov IJ; Melnicharov MB; Kunev KV; Mitev VI; Kaneva RP; Goranova TE
    Pathol Oncol Res; 2015 Apr; 21(2):413-21. PubMed ID: 25149524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
    Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
    Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.
    Russo A; Corsale S; Agnese V; Macaluso M; Cascio S; Bruno L; Surmacz E; Dardanoni G; Valerio MR; Vieni S; Restivo S; Fulfaro F; Tomasino RM; Gebbia N; Bazan V
    J Cell Physiol; 2006 Jan; 206(1):181-8. PubMed ID: 15965904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing of locally advanced squamous cell carcinomas of the head and neck reveals druggable targets for improving adjuvant chemoradiation.
    Tinhofer I; Budach V; Saki M; Konschak R; Niehr F; Jöhrens K; Weichert W; Linge A; Lohaus F; Krause M; Neumann K; Endris V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Baumann M;
    Eur J Cancer; 2016 Apr; 57():78-86. PubMed ID: 26896955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cdkn2a suppresses metastasis in squamous cell carcinomas induced by the gain-of-function mutant p53(R172H).
    Li Z; Gonzalez CL; Wang B; Zhang Y; Mejia O; Katsonis P; Lichtarge O; Myers JN; El-Naggar AK; Caulin C
    J Pathol; 2016 Oct; 240(2):224-34. PubMed ID: 27447534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P16(INK⁴a) overexpression is associated with CDKN2A mutation and worse prognosis in HPV-negative laryngeal squamous cell carcinomas.
    Larque AB; Conde L; Hakim S; Alos L; Jares P; Vilaseca I; Cardesa A; Nadal A
    Virchows Arch; 2015 Apr; 466(4):375-82. PubMed ID: 25652585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homozygous deletions of UGT2B17 modifies effects of smoking on TP53-mutations and relapse of head and neck carcinoma.
    Mafune A; Hama T; Suda T; Suzuki Y; Ikegami M; Sakanashi C; Imai S; Nakashima A; Yokoo T; Wada K; Kojima H; Urashima M
    BMC Cancer; 2015 Mar; 15():205. PubMed ID: 25886176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
    Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
    Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and characterization of a novel HPV-negative laryngeal squamous cell carcinoma cell line, FD-LSC-1, with missense and nonsense mutations of TP53 in the DNA-binding domain.
    Wu CP; Zhou L; Gong HL; Du HD; Tian J; Sun S; Li JY
    Cancer Lett; 2014 Jan; 342(1):92-103. PubMed ID: 24001612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.
    Deneka AY; Baca Y; Serebriiskii IG; Nicolas E; Parker MI; Nguyen TT; Xiu J; Korn WM; Demeure MJ; Wise-Draper T; Sukari A; Burtness B; Golemis EA
    Clin Cancer Res; 2022 May; 28(9):1925-1937. PubMed ID: 35491653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
    Poeta ML; Manola J; Goldwasser MA; Forastiere A; Benoit N; Califano JA; Ridge JA; Goodwin J; Kenady D; Saunders J; Westra W; Sidransky D; Koch WM
    N Engl J Med; 2007 Dec; 357(25):2552-61. PubMed ID: 18094376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impairment of MLH1 and CDKN2A in oncogenesis of laryngeal cancer.
    Sasiadek MM; Stembalska-Kozlowska A; Smigiel R; Ramsey D; Kayademir T; Blin N
    Br J Cancer; 2004 Apr; 90(8):1594-9. PubMed ID: 15083191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck.
    Nylander K; Dabelsteen E; Hall PA
    J Oral Pathol Med; 2000 Oct; 29(9):413-25. PubMed ID: 11016683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Homozygous deletion of p16 and p15 genes in laryngeal squamous cell carcinoma].
    Li F; Kang N; Li Y; He G; Lin C; Sun X; Gao H; Sun K
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Feb; 19(1):30-2. PubMed ID: 11836682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
    Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
    Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck.
    Alsner J; Sørensen SB; Overgaard J
    Radiother Oncol; 2001 May; 59(2):179-85. PubMed ID: 11325447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours.
    Jefferies S; Edwards SM; Hamoudi RA; A'Hern R; Foulkes W; Goldgar D; Eeles R;
    Br J Cancer; 2001 Nov; 85(9):1383-6. PubMed ID: 11720478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation of CDKN2A, MGMT, MLH1, and DAPK genes in laryngeal squamous cell carcinoma and their associations with clinical profiles of the patients.
    Pierini S; Jordanov SH; Mitkova AV; Chalakov IJ; Melnicharov MB; Kunev KV; Mitev VI; Kaneva RP; Goranova TE
    Head Neck; 2014 Aug; 36(8):1103-8. PubMed ID: 23804521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.